Published AAO appeal decisions

Bioengineer in precision medicine and drug discovery met first Dhanasar prong with substantial merit and national importance. However, lacked PhD and did not demonstrate sufficient progress, plan, or stakeholder interest required for second prong. Appeal dismissed.

Chemical engineer with five years pharmaceutical and biotechnology experience sought EB-2 with national interest waiver. Proposed developing analytical methods and processes for vaccine and therapeutic manufacturing. AAO dismissed because petitioner failed to demonstrate proposed work has national importance; work appeared routine to employer without broader industry impact.

An employer sought a national interest waiver for a beneficiary as associate vice president in pharmaceutical supply chain management. The AAO held the proposed endeavor lacked demonstrated national importance under Dhanasar's first prong because work would not impact the field broadly, merely addressing company-specific needs despite being in an important sector.

A nicotine manufacturer petitioned for a director of product development under EB-2 advanced degree and Schedule A Group II. The beneficiary met two of seven evidentiary criteria (judging and scholarly articles). The AAO affirmed denial because the record did not demonstrate widespread acclaim and international recognition required for Schedule A designation.

A senior scientist with doctoral degree in biology at a multinational pharmaceutical company sought NIW for EB-2. The AAO dismissed appeal after finding proposed drug design research endeavor lacks national importance. Published work and connection to broad health initiatives insufficient; specific endeavor impact not demonstrated at national scale.

An employer petitioned for NIW for study management associate II overseeing oncology and hematology clinical trials for advanced therapies. AAO affirmed denial: while the work was meritorious, petitioner failed to show the specific endeavor had national importance or substantial economic impact beyond the employer's clients and consumers.

Biotechnology researcher proposes developing genomic editing tools for disease modeling and gene therapy targeting neurodegenerative and autoimmune disorders. AAO found the endeavor has substantial merit but rejected it because the record fails to establish the proposed endeavor's prospective impact or national importance, relying instead on general industry importance.

Clinical pharmacologist employed by biopharmaceutical company met three initial evidentiary criteria but lacked sustained national or international acclaim demonstrating placement among the very top of field in pharmacokinetics and pharmacodynamics; appeal dismissed on final merits.

Doctoral candidate in medical research seeking EB-2 NIW for developing medical devices for organ preservation and hypoxia treatment. AAO found first prong met but dismissed, finding petitioner not well-positioned to advance endeavor due to lack of Ph.D. at filing and insufficient connection of prior research to proposed medical device work.